Sclerosis multiplex (SM): vizsgálatok itt: Olaszország
54 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Catania, Cefalu', Chieti Scalo, Florence, Messina, Milan, Naples, Orbassano, Pozzilli, Rome
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - No phaseTaking peopleMotor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
- Where
- Messina
- Életkor
- 18 év to 70 év
- People
- 150
- Run by
- IRCCS Centro Neurolesi Bonino Pulejo
See details and how to joinNCT07066137 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Catania, Cefalu', Chieti Scalo, Genoa, Milan, Naples, Orbassano, Pozzilli, Rome
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Chieti, Como, Florence, Foggia, Milan, Monza, Palermo, Pozzilli, Rome, Verona
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Bergamo, Foggia, Genoa, Milan, Pavia, Rome
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Bologna, Catania, Cefalu', Florence, Milan, Naples, Rome, Siena
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 2. fázisTaking peopleFoetal neural stem cells transplantation in progressive multiple sclerosis
- Where
- Bergamo, Como, Milan, Monza, Pavia
- Életkor
- 18 év and over
- People
- 86
- Run by
- Ospedale San Raffaele S.r.l.
See details and how to join2024-511028-15-00 · EU 2024-511028-15-00 - No phaseNot yet taking people in OlaszországDual-Task Balance Training in People With Multiple Sclerosis: a Randomized Feasibility Study
- Where
- Verona
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Universita di Verona
See details and how to joinNCT07878702 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Ancona, Bergamo, Chieti, Foggia, Gallarate, Naples, Pavia, Pozzilli, Roma
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Cagliari, Foggia, Milan, Modena, Parma, Perugia, Rome, Rozzano, Verona
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - No phaseNot yet taking people in OlaszországBridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
- Where
- Milan, Verona
- Életkor
- 18 év and over
- People
- 192
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07856485 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Chieti Scalo, Genoa, Milan, Naples, Pavia, Rome, Salerno
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Naples, Rome
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 3. fázisTaking peopleStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Where
- Milan, Naples, Rome
- Életkor
- 10 év to 17 év
- People
- 194 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00 - 2. fázisTaking peopleA Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
- Where
- Cefalu', Florence, Montichiari, Pozzilli, Rome
- Életkor
- 18 év to 64 év
- People
- 93 worldwide
- Run by
- Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Ancona, Bergamo, Cagliari, Chieti Scalo, Foggia, Gallarate (VA), Naples, Orbassano, Pavia, Pozzilli, Rome
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - No phaseTaking peopleOptical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
- Where
- Milan
- Életkor
- 18 év and over
- People
- 1050
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07720765 - No phaseTaking peopleSonification Techniques for Gait Training
- Where
- Pavia
- Életkor
- Up to 80 év
- People
- 120
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT04876339 - 4. fázisTaking peopleEffects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life
- Where
- Milan
- Életkor
- 18 év to 64 év
- People
- 30
- Run by
- Ospedale San Raffaele S.r.l.
See details and how to join2024-513960-24-00 · EU 2024-513960-24-00 - No phaseTaking peopleATLG Levels in Autologous HSCT for Multiple Sclerosis
- Where
- Milan
- Életkor
- 18 év and over
- People
- 20
- Run by
- Ciceri Fabio
See details and how to joinNCT07635693 - No phaseCsak meghívásosThe Italian Multiple Sclerosis and Related Disorders Register
- Where
- Genova
- People
- 96 000
- Run by
- Fondazione Italiana Sclerosi Multipla
See details and how to joinNCT07636876 - No phaseNot yet taking people in OlaszországEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients
- Where
- Bari, Costa Masnaga, Milan, Montescano, Pavia, Pisa, Telese Terme
- Életkor
- 18 év and over
- People
- 70
- Run by
- Marta Mondellini
See details and how to joinNCT07616050 - No phaseNot yet taking people in OlaszországOlfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study
- Where
- Catania
- Életkor
- 18 év to 55 év
- People
- 200
- Run by
- University of Catania
See details and how to joinNCT06020937 - No phaseTaking peopleAuditory Functions in Patients With Multiple Sclerosis
- Where
- Catania
- Életkor
- 20 év to 40 év
- People
- 30
- Run by
- University of Catania
See details and how to joinNCT06164483 - No phaseTaking peopleDefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
- Where
- Naples, Telese Terme
- Életkor
- 18 év and over
- People
- 60
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT05748015